Angioslide launches new 300mm long Proteus device in Europe


On 8 September 2011, Angioslide announced the first procedures with its new 5x300mm Proteus device for treating the superficial femoral artery. Proteus technology combines a percutaneous transluminal angioplasty balloon and embolic capture of particles in one device. The new 5x300mm size joins Angioslide’s current dedicated product line solutions for the lower limbs.

Initial treatments using the new Proteus device were conducted in leading world centres, Parkkrankenhaus Leipzig and Herzzentrum Bad Krozingen, in Germany. The Proteus 5X300mm makes it possible to treat lesions up to 300mm with one device, while providing an immediate solution for embolic capture.


“Angioslide’s breakthrough technology, now available also in 300mm length as well, is a unique solution for lesions with high level of embolic material, including chronic total occlusions, in stent-restenosis, thrombus containing lesions and post atherectomy angioplasty,” said Thomas Zeller, head of the Angiology Department, Heart Center Bad Krozingen.


Dierk Scheinert, head of the Department of Angiology, Park-Krankenhaus Leipzig added “We have been using the Proteus product line as part of our daily practice for a few years, and are working closely with the Angioslide team. I welcome the release of the 5X300mm. We can now use one device to treat patients with superficial femoral artery disease, which facilitates the procedural flow and makes the intervention cost-effective.”

“We are committed to introducing new products to the market continuously, addressing the growing range of endovascular solutions,” said Lihu Avitov, Angioslide CEO. “With patients’ needs in mind, the 5X300mm device is the first in a series of long balloons, adding to our current offering of 20–100mm devices. The Proteus product family provides additional confidence to clinicians treating their endovascular patients.”


The Proteus 5X300mm is currently released for the European market only, and is undergoing an evaluation regulatory process with the FDA.